PureTech Health plc (PTCHF) stock
Close on Oct 19, 2026Market cap –P/E –Yield –
PureTech Health plc saw revenue fall 3.5% to $4.66M over fiscal 2025. Free cash flow was -$85.14M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $4.66M
- Net income
- -$109.74M
- EPS, diluted
- -$0.46
- Free cash flow
- -$85.14M
Trading
- Previous close
- $1.48
- Open
- $1.48
- Day's range
- $1.48 – $1.48
- Volume
- 0
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | PTCHF | S&P 500 | Difference | PTCHF per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -10.4% | +0.6% | −11.0 pts | ||
| 3 months | -7.3% | +3.4% | −10.7 pts | ||
| Year to date | -13.2% | +13.3% | −26.5 pts | ||
| 1 year | -11.9% | +16.6% | −28.5 pts | ||
| 3 years | -22.5% | +86.4% | −108.9 pts | -8.2% | +23.1% |
| 5 years | -70.3% | +81.9% | −152.1 pts | -21.5% | +12.7% |
| 10 years | -21.3% | +318.9% | −340.1 pts | -2.4% | +15.4% |
Nine years at a glance
Fiscal years 2017 to 2025, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases PureTech Health filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About PureTech Health
Pharmaceutical Preparations
PureTech Health operates as a biotherapeutics entity focused on developing treatments across several dedicated operational segments, primarily targeting oncology and related clinical areas through subsidiary operating units. The company conducts its research and development programs both directly and through subsidiary operating companies such as Gallop Oncology, Entrega, PureTech LYT, and PureTech LYT 100. These programs are designed to advance targeted biotherapeutic candidates for patients, while also managing historical interests in deconsolidated former subsidiaries and inactive corporate entities.
Company profile, executives and historyPureTech Health stock: common questions
What is PureTech Health's stock price?
PTCHF closed at $1.48 on Oct 19, 2026, up 0.00% on the day.
What is PTCHF's P/E ratio?
PureTech Health lost money over fiscal 2025 (diluted EPS -$0.46), so it has no meaningful P/E ratio.
How much revenue does PureTech Health make?
PureTech Health reported revenue of $4.66M for fiscal 2025, down 3.5% from a year earlier.
Does PureTech Health pay a dividend?
No. PureTech Health has not paid a cash dividend over the last twelve months.
How has PTCHF stock performed over the past year?
Including dividends, PTCHF returned -11.9% over the past year, against +16.6% for the S&P 500.
Who are PureTech Health's competitors?
Companies most similar to PureTech Health by business, industry and size include ANL, APLM, BOLT, IMNM, RANI.
See a number that looks wrong?